[Disclosure] Alteogen (196170) Submits FY17 Audit Report; Confirms ‘Unqualified’ Audit Opinions and Turnaround to Profit

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-03-21

Disclosure Type: Submission of Audit Report

💡 3-Second Summary

Alteogen has received an ‘Unqualified’ audit opinion from Samil PwC for its 17th fiscal year financial statements, officially establishing consolidated revenue of approx. KRW 102.8B and operating income of approx. KRW 25.4B, marking a successful turnaround to profitability.

📊 1. [Summary of Core Disclosure Content and Key Figures]

• Independent Auditor: Samil PricewaterhouseCoopers (Report received date: March 21, 2025)
• Audit Opinions & Going Concern Status: ‘Unqualified’ (Clean opinion) for both consolidated and separate statements (No material uncertainty related to going concern)
• FY17 Consolidated Financial & Income Parameters (In KRW):
  • Total Assets: 409,011,974,213 / Total Liabilities: 134,920,913,122 / Total Equity: 274,091,061,091
  • Revenue: 102,854,620,800 (Prior Year: 96,522,928,887)
  • Operating Income: 25,403,990,856 (Prior Year: -9,736,838,487, turned to profit)
  • Net Income: 60,690,355,931 (Prior Year: -3,582,208,686, turned to profit)
• FY17 Separate Financial & Income Parameters (In KRW):
  • Total Assets: 331,648,013,253 / Total Liabilities: 30,521,082,514 / Total Equity: 301,126,930,739
  • Revenue: 92,969,044,752 (Prior Year: 83,478,376,310)
  • Operating Income: 30,629,830,861 (Prior Year: -904,325,264, turned to profit)
  • Net Income: 71,232,721,344 (Prior Year: 4,870,807,532)
• Other Metrics: 2 consolidated subsidiaries, 1 major subsidiary, Capital Impairment Ratio is not applicable (-), Impairment Loss Ratio over 50% is ‘No’.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This regulatory filing acts as an administrative verification publishing that Alteogen’s financial books have cleared professional cross-examinations by an external auditor without any accounting inconsistencies. This process transforms provisional management figures into finalized, statutory numbers, allowing market participants to rely on the confirmed parameters and baseline structural accuracy.

From a statistical standpoint, the key observation is that consolidated and separate revenues are greater than their respective operating incomes, validating standard internal consistency. The company demonstrated a complete reversal from its prior operational deficits, securing positive consolidated income before income taxes of approx. KRW 36.6B (approx. KRW 47.1B on a separate basis) with no impairment triggers. While an unqualified evaluation from a major accounting firm may support administrative stability, the disclosure does not explain the specific causes of financial performance fluctuations. Therefore, investors are advised to interpret this report as a formal technical confirmation of corporate metrics rather than a definitive predictor of forward-looking earnings trajectories, keeping focus on the business fundamentals.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen has officially filed its 17th annual audit report with an unqualified opinion from Samil PwC. This document presents the final, validated figures regarding the company’s financial allocations before the annual general meeting. On a consolidated basis, revenue successfully crossed KRW 102.8B while operating income hit KRW 25.4B, cementing its pivot back into profitable execution. Key risks like historical impairment losses or consecutive operational deficits remain completely cleared as verified by the documented parameters. Market participants should review these finalized structural metrics objectively based purely on official timelines.

📢 Disclaimer and Source Information

Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.